Day One Biopharmaceuticals Files 8-K Report
Ticker: DAWN · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1845337
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Day One Bio just filed an 8-K, check for updates.
AI Summary
On March 4, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events beyond the filing itself are detailed in the provided text.
Why It Matters
This filing indicates that Day One Biopharmaceuticals is making a regulatory submission to the SEC, which could contain important updates for investors.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Registrant
- 0001193125-24-062203 (accession_number) — Filing identifier
- 20240307 (date) — Filing date
- March 4, 2024 (date) — Earliest event reported date
- 2000 Sierra Point Parkway, Suite 501 (address) — Principal executive offices
- Brisbane, California (location) — Principal executive offices location
- 94005 (zip_code) — Principal executive offices zip code
- 650 484-0899 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of March 4, 2024.
When was this 8-K report filed with the SEC?
This 8-K report was filed on March 7, 2024.
What is the exact name of the company filing this report?
The exact name of the company is Day One Biopharmaceuticals, Inc.
Where are Day One Biopharmaceuticals' principal executive offices located?
Day One Biopharmaceuticals' principal executive offices are located at 2000 Sierra Point Parkway, Suite 501, Brisbane, California, 94005.
What is the telephone number for Day One Biopharmaceuticals?
The telephone number for Day One Biopharmaceuticals is (650) 484-0899.
Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-03-07 16:19:02
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share DAWN Nasdaq Global Select
- $5 million — ime payment in March 2024 to Viracta of $5 million in exchange for reduced future payment
- $49 million — ake further milestone payments of up to $49 million upon achievement of specified developme
Filing Documents
- d764767d8k.htm (8-K) — 26KB
- d764767dex101.htm (EX-10.1) — 14KB
- 0001193125-24-062203.txt ( ) — 161KB
- dawn-20240304.xsd (EX-101.SCH) — 3KB
- dawn-20240304_lab.xml (EX-101.LAB) — 18KB
- dawn-20240304_pre.xml (EX-101.PRE) — 11KB
- d764767d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Amendment No. 1 to the License Agreement for RAF, dated March 4, 2024, by and between Day One Biopharmaceuticals, Inc. and Sunesis Pharmaceuticals, Inc. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: March 7, 2024 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer